Grants

This grant supports proposals that demonstrate disruptive impact on defence applications, aiming to accelerate the creation and deployment of novel solutions for armed forces and to foster the uptake of new civilian innovations in the defence sector. Projects should enhance operational readiness, improve strategic decision-making, and address emerging threats through cutting-edge technologies or products. Funded actions should advance disruptive knowledge, products or technologies in any area of defence interest, achieving at least TRL4, with a focus on rapid time-to-market and a duration typically between 12 and 24 months.

The grant supports disruptive research and innovation for defence applications. Proposals must demonstrate disruptive impact in innovative technologies or solutions that improve readiness, deployability, reliability, safety, or sustainability of defence forces; this includes operations, equipment, infrastructure, energy solutions, surveillance or digital systems. Projects may adapt solutions from civilian applications that have not yet been applied in defence. Proposals must address disruptive knowledge, products, and technologies reaching at least TRL 4. The expected duration for each funded action is between 12 and 36 months, with a maximum EU contribution of EUR 5,000,000 per project.

EIC Transition funds innovation activities beyond experimental proof of principle in the laboratory (projects must have completed all elements of Technology Readiness Level 3). It supports both the maturation and validation of novel technologies from the lab to relevant application environments (such as through prototyping, user testing, or other validation tests), as well as exploration and development of a sustainable business plan and model toward commercialization in high potential markets. Supported projects must further develop technology from results achieved in a prior project, applying user-centric methodologies to increase the chances of future commercial success. Activities should include a balanced mix of additional technology development/validation and market/business development, including customer/user feedback. By project end, technologies should advance beyond proof of concept (end goal: TRL 5–6), supported by a validated business plan, market research, and aspects such as intellectual property, regulation, and investment readiness.

This action supports the follow-up to the July 2023 Communication on EU Missions assessment. The programme aims to create a network of registered cancer charities and funding agencies supporting transnational research and innovation projects focused on improving the quality of life of young cancer patients and survivors (children, adolescents, and young adults). Supported projects will enhance physical, emotional, and social well-being and stimulate the accessibility and re-usability of digital data for research, contributing to the future UNCAN.eu data platform. The action targets challenges faced by survivors, their families, and caregivers, delivering innovative solutions and fostering collaboration and open science across EU Member States and Associated Countries.

This action supports the development and procurement of affordable, innovative solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines. It aims to stimulate the competitive development of market-ready innovations that are cost-efficient, safe, and benefit cancer patients living with and beyond cancer. The procurement consortia must include public procurers (possibly in cooperation with private entities) and involve end-user engagement and participative research models. Solutions should be clinically validated, piloted, or upscaled in at least five different EU or Associated Countries. The project facilitates commercialisation, provides first customer references for suppliers, and supports the adoption of best practices by policymakers, healthcare providers, professionals, cancer patients, and carers.

This grant seeks to enhance equitable health outcomes and deliver added value for people at risk of cancer and cancer patients by supporting research in health economics, health systems, epidemiology, and outcomes. Projects should establish or refine research methods for performing cost-effectiveness and epidemiological analyses, improve access to effective cancer control programmes, and support the development of value-based, patient-centred healthcare. Proposals must address socio-economic and socio-demographic inequalities, engage patients and caregivers, and consider regional diversity in healthcare delivery across Europe.

This grant supports phase 1, including first-in-human multi-centre clinical trials, to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes. Its objectives are to ensure patients with these cancers have access to tailored, innovative medicines or treatment approaches, to enable researchers and professionals to validate or commercialise promising approaches, and to provide health authorities across Europe with evidence of safety and efficacy to inform further clinical development.

This grant aims to support evidence-based, tailored, innovative, affordable, and accessible clinical research projects for lung, bowel, breast, or prostate cancer, led by comprehensive cancer infrastructures. Projects should benefit patients afflicted by these cancers by delivering improved diagnostic and treatment programmes, and by fostering collaboration among researchers, healthcare providers, innovators, patients, and stakeholders. The grants also seek to reduce inequalities in research capacity and healthcare provision across European Union Member States and Associated Countries, with a focus on piloting and upscaling solutions in diverse regions, including those with less developed infrastructures.

This grant aims to advance the understanding of tumour heterogeneity in cancer initiation and progression, identify novel therapeutic targets, and support the development of next-generation genomically-informed cancer treatments. Projects will focus on integrating and analysing complex, multimodal patient data using advanced methodologies, with an emphasis on paediatric and adolescent cancers, cancers with limited treatment options, refractory or rare cancers, and cancers with low five-year survival rates.